CClinicalTrials.gg
TerminatedNCT04422951Updated Oct 16, 2023Results posted

Wise Social Psychological Interventions to Improve Outcomes of Behavioral Weight Control in Children With Obesity

An interventional study of Wise interventions -- values self-affirmation and growth mindset -- plus usual care behavioral treatment and Education plus usual care behavioral treatment in Obesity, Childhood, sponsored by Stanford University. Terminated at 1 site in United States. Open to participants aged 10 Years to 16 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-16.

Sponsored by Stanford University · Not applicable, Interventional, and Treatment

Why this study was terminated
Delays and complications due to the Covid pandemic
Phase
Not applicable
Study type
Interventional
Enrollment
2
Allocation
Randomized
Ages
10 Years to 16 Years
Sex
All
01

Study summary

A 2-arm, parallel group, randomized controlled trial to evaluate overall differences in body mass index (BMI) trajectories over 6 months between 10-16-year-old children with obesity randomized to receive the wise social psychological interventions plus a usual care behavioral intervention for weight management compared to children randomized to receive additional education plus a usual care behavioral intervention.

02

Conditions studied

  • Obesity, Childhood
03

In context

Obesity

6,296 studies on the registry are indexed under Obesity; 1,695 are open to participants now.

This study's enrollment of 2 is below the median of 78 across 4,878 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Stanford University is the lead sponsor of 2,117 studies on the registry; 425 are open to participants now.

Of its 259 completed or terminated interventional studies of FDA-regulated products, 197 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • 10-16 year old children with obesity (BMI ≥ 95th percentile on the 2000 Centers for Disease Control and Prevention BMI reference) on the date of randomization. Participation in a behavioral weight control program. Standard behavioral weight control program eligibility criteria will apply: Child and at least one parent/guardian must agree to participate

Exclusion criteria

Exclusion Criteria:

  • Medical conditions affecting growth - diagnosed with a genetic or metabolic disease/syndrome associated obesity, Type 1 diabetes, Type 2 diabetes taking medication, chronic gastrointestinal diseases, Chronic renal diseases, uncorrected structural heart disease, heart failure, heart transplant, anorexia nervosa or bulimia nervosa or binge eating disorder (present or past), AIDS or HIV infection, pregnancy

Medications affecting growth - systemic corticosteroids more than 2 weeks in the past year, insulin, oral hypoglycemics, thyroid hormone, growth hormone

Conditions limiting participation in the interventions - e.g., unable to participate in routine physical education classes at school, requiring oxygen supplementation for exertion, developmental or physical disability preventing participation in interventions, children or parents/guardians who cannot medically participate in mild dietary restrictions and/or increased physical activity for any reason

Conditions limiting participation in the assessments - child or primary caregiver not able to read surveys in English or Spanish, child two or more grade levels delayed in school for reading and writing in his/her native language

Unable to read, understand or complete informed consent in English or Spanish

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    Wise interventions plus behavioral Rx

    Wise social psychological interventions (growth mindset and values self-affirmation) plus a usual care behavioral intervention for weight control.

    Behavioral: Wise interventions -- values self-affirmation and growth mindset -- plus usual care behavioral treatment

  • Active comparator
    Education plus behavioral Rx

    Health education plus a usual care behavioral intervention for weight control

    Behavioral: Education plus usual care behavioral treatment

Interventions

  • BehavioralWise interventions -- values self-affirmation and growth mindset -- plus usual care behavioral treatment

    Addition of two wise wise social psychological interventions-growth mindset and self-affirmation-to a 6-month usual care behavioral intervention for weight control in children with obesity

  • BehavioralEducation plus usual care behavioral treatment

    6-month health education plus usual care behavioral intervention for weight control in children with obesity

06

What researchers measure

Primary outcomes

  1. Change in Body Mass Index From Baseline to 6 Months

    body mass index = weight in kilograms divided by the squared height in meters

    Time frame: Change from baseline to 6 months

07

Results

Posted Oct 16, 2023
Limitations and caveats
This study did not meet its planned enrollment and did not achieve statistical power.

Participant flow

To enter the study, the child and at least one parent/guardian must have agreed to participate, and both child and adult were considered to be enrolled.

Participant flow — Overall Study
MilestoneWise Interventions Plus Behavioral RxEducation Plus Behavioral Rx
Started02
Completed00
Not completed02

Outcome measures

PrimaryChange in Body Mass Index From Baseline to 6 Months

body mass index = weight in kilograms divided by the squared height in meters

Time frame:
Change from baseline to 6 months

No measurements were reported for this outcome.

Adverse events

Collected over Up to 2.5 months, when participation ended.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Education Plus Behavioral Rx0/2 (0%)0/2 (0%)0/2 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Education Plus Behavioral Rx
<=18 years1
Between 18 and 65 years1
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Education Plus Behavioral Rx
Female2
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Education Plus Behavioral Rx
Hispanic or Latino0
Not Hispanic or Latino2
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Education Plus Behavioral Rx
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American2
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Education Plus Behavioral Rx
United States2
08

Study locations

1 site
  • Stanford University
    Stanford, California 94305, United States
09

References and documents

Study documents

  • Study protocol · Apr 30, 2023
  • Statistical analysis plan · May 13, 2022

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — Data sharing will be based on the policy for data sharing issued by the NIH and consistent with HIPAA privacy standards. Our data management team will prepare de-identified public use data set from this study for deposition in a repository.

Supporting information: Study protocol, Sap, Icf

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 16, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04422951
Lead sponsor
Stanford University
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Responsible party
Thomas Robinson (Professor, Stanford University) — Principal investigator
First posted
Jun 9, 2020
Start date
Apr 6, 2023
Primary completion
Jun 20, 2023
Completion
Jun 20, 2023
Results posted
Oct 16, 2023
Last update
Oct 16, 2023

Study contacts

Thomas Robinson, MD, MPH
principal investigator · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion